Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMMX Immix Biopharma	$2.17 -3.1%	$2.14	$1.26 ▼ $3.00	$60.49M	0.31	153,976 shs	170,910 shs
NGNE Neurogene	$16.16 -2.5%	$17.33	$6.88 ▼ $74.49	$230.47M	1.57	246,333 shs	436,968 shs
TNXP Tonix Pharmaceuticals	$34.89 -1.8%	$28.59	$6.76 ▼ $130.00	$256.69M	2.09	950,006 shs	1.94 million shs
TVRD Tvardi Therapeutics	$24.61 -2.4%	$0.00	$8.13 ▼ $34.31	$230.37M	0.25	75,221 shs	515,028 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMMX Immix Biopharma	-3.13%	-3.13%	+11.28%	+27.65%	-1.36%
NGNE Neurogene	-2.47%	-9.01%	-8.49%	+11.29%	-49.52%
TNXP Tonix Pharmaceuticals	-1.83%	+7.82%	-7.43%	+72.98%	-68.99%
TVRD Tvardi Therapeutics	-2.38%	-4.50%	-20.25%	+2,460,999,900.00%	+2,460,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IMMX Immix Biopharma	3.6249 of 5 stars	3.5	5.0	0.0	0.0	2.2	3.3	0.6
NGNE Neurogene	3.9483 of 5 stars	4.4	3.0	0.0	0.0	2.7	2.5	1.3
TNXP Tonix Pharmaceuticals	2.7797 of 5 stars	3.5	2.0	0.0	0.0	2.0	3.3	0.6
TVRD Tvardi Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMMX Immix Biopharma	3.00	Buy	$7.00	222.58% Upside
NGNE Neurogene	2.75	Moderate Buy	$46.17	185.68% Upside
TNXP Tonix Pharmaceuticals	3.00	Buy	$585.00	1,576.70% Upside
TVRD Tvardi Therapeutics	3.00	Buy	$71.50	190.53% Upside

Current Analyst Ratings Breakdown

Latest IMMX, NGNE, TNXP, and TVRD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	NGNE Neurogene	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
6/12/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$22.00 ➝ $26.00
6/12/2025	TVRD Tvardi Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$78.00
6/4/2025	IMMX Immix Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
6/3/2025	TNXP Tonix Pharmaceuticals	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/21/2025	TVRD Tvardi Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
5/20/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $22.00
5/16/2025	NGNE Neurogene	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	NGNE Neurogene	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$38.00 ➝ $24.00
5/13/2025	NGNE Neurogene	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $45.00
4/14/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$45.00 ➝ $16.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	$0.48 per share	N/A
NGNE Neurogene	$930K	247.79	N/A	N/A	$20.89 per share	0.77
TNXP Tonix Pharmaceuticals	$10.09M	25.45	N/A	N/A	$31.82 per share	1.10
TVRD Tvardi Therapeutics	$7.14M	32.26	N/A	N/A	($3.02) per share	-8.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMMX Immix Biopharma	-$21.61M	-$0.70	N/A	N/A	N/A	N/A	-130.02%	-86.33%	8/11/2025 (Estimated)
NGNE Neurogene	-$75.14M	-$4.35	N/A	N/A	N/A	N/A	-36.16%	-32.51%	8/8/2025 (Estimated)
TNXP Tonix Pharmaceuticals	-$130.04M	-$1,963.61	N/A	N/A	N/A	-1,313.87%	-120.96%	-101.28%	8/15/2025 (Estimated)
TVRD Tvardi Therapeutics	-$70.87M	N/A	0.00	∞	N/A	-595.39%	-710.04%	-79.00%	N/A

Latest IMMX, NGNE, TNXP, and TVRD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/12/2025	Q1 2025	TNXP Tonix Pharmaceuticals	-$3.23	-$2.84	+$0.39	-$2.84	$2.55 million	$2.43 million
5/9/2025	Q1 2025	NGNE Neurogene	-$1.05	-$1.08	-$0.03	-$1.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	N/A
NGNE Neurogene	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TVRD Tvardi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMMX Immix Biopharma	N/A	1.80	1.80
NGNE Neurogene	N/A	21.03	21.03
TNXP Tonix Pharmaceuticals	N/A	12.31	11.64
TVRD Tvardi Therapeutics	N/A	32.48	31.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMMX Immix Biopharma	11.26%
NGNE Neurogene	52.37%
TNXP Tonix Pharmaceuticals	82.26%
TVRD Tvardi Therapeutics	44.66%

Insider Ownership

Company	Insider Ownership
IMMX Immix Biopharma	55.40%
NGNE Neurogene	11.64%
TNXP Tonix Pharmaceuticals	0.03%
TVRD Tvardi Therapeutics	3.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMMX Immix Biopharma	9	27.88 million	12.43 million	Optionable
NGNE Neurogene	90	14.26 million	12.60 million	Optionable
TNXP Tonix Pharmaceuticals	50	7.36 million	7.36 million	Not Optionable
TVRD Tvardi Therapeutics	80	9.36 million	9.07 million	N/A

IMMX, NGNE, TNXP, and TVRD Headlines

Recent News About These Companies

Tvardi Therapeutics Inc News (TVRD) - Investing.com

June 27 at 6:35 PM | investing.com

TVRD Tvardi Therapeutics, Inc.

June 19, 2025 | seekingalpha.com

Piper Sandler initiates Tvardi Therapeutics stock with overweight rating

June 13, 2025 | uk.investing.com

Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside

June 12, 2025 | benzinga.com

Cara Therapeutics (NASDAQ:TVRD) Coverage Initiated by Analysts at Piper Sandler

June 12, 2025 | marketbeat.com

Tvardi Therapeutics Inc (TVRD)

June 7, 2025 | investing.com

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis

May 27, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMX, NGNE, TNXP, and TVRD Company Descriptions

Immix Biopharma NASDAQ:IMMX

$2.17 -0.07 (-3.13%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.17 +0.00 (+0.23%)

As of 06/27/2025 06:43 PM Eastern

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Neurogene NASDAQ:NGNE

$16.16 -0.41 (-2.47%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$15.88 -0.28 (-1.70%)

As of 06/27/2025 05:45 PM Eastern

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Tonix Pharmaceuticals NASDAQ:TNXP

$34.89 -0.65 (-1.83%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$34.56 -0.33 (-0.95%)

As of 06/27/2025 07:58 PM Eastern

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Tvardi Therapeutics NASDAQ:TVRD

$24.61 -0.60 (-2.38%)

As of 06/27/2025 04:00 PM Eastern

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time